Trial Profile
A post-marketing surveillance study of safety and effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 01 Apr 2022 Results published in the International Journal of Hematology
- 18 Apr 2017 New trial record